| __timestamp | BeiGene, Ltd. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 26684000 |
| Thursday, January 1, 2015 | 7311000 | 29829000 |
| Friday, January 1, 2016 | 20097000 | 39578000 |
| Sunday, January 1, 2017 | 62602000 | 43277000 |
| Monday, January 1, 2018 | 195385000 | 48645000 |
| Tuesday, January 1, 2019 | 388249000 | 52934000 |
| Wednesday, January 1, 2020 | 600176000 | 61349000 |
| Friday, January 1, 2021 | 990123000 | 127125000 |
| Saturday, January 1, 2022 | 1277852000 | 136106000 |
| Sunday, January 1, 2023 | 1504501000 | 133175999 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, BeiGene, Ltd. and HUTCHMED (China) Limited have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BeiGene's SG&A expenses skyrocketed by over 21,600%, reflecting its aggressive expansion and investment in global operations. In contrast, HUTCHMED's expenses grew by approximately 400%, indicating a more measured approach. By 2023, BeiGene's expenses were nearly 11 times higher than HUTCHMED's, highlighting its rapid growth strategy. This divergence underscores the different paths these companies are taking in the competitive biotech landscape. Investors and industry watchers should consider these trends when evaluating the companies' future potential and strategic directions.
Operational Costs Compared: SG&A Analysis of GSK plc and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
CymaBay Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends